520 related articles for article (PubMed ID: 26605871)
1. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.
Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y
Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945
[TBL] [Abstract][Full Text] [Related]
3. Serum cripto-1 as a clinical marker for lung cancer.
Xu CH; Cao L; Wei Y; Yu LK
Int J Biol Markers; 2015 Nov; 30(4):e369-73. PubMed ID: 26109366
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of serum periostin in patients with non-small cell lung cancer.
Xu CH; Wang W; Lin Y; Qian LH; Zhang XW; Wang QB; Yu LK
Oncotarget; 2017 Mar; 8(12):18746-18753. PubMed ID: 27816968
[TBL] [Abstract][Full Text] [Related]
5. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer.
Cho A; Hur J; Hong YJ; Lee HJ; Kim YJ; Hong SR; Suh YJ; Im DJ; Kim YJ; Lee JS; Shim HS; Choi BW
Tumour Biol; 2016 Mar; 37(3):3205-13. PubMed ID: 26432331
[TBL] [Abstract][Full Text] [Related]
7. High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.
Park KS; Moon YW; Raffeld M; Lee DH; Wang Y; Giaccone G
Lung Cancer; 2018 Feb; 116():38-45. PubMed ID: 29413049
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
9. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
10. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and Prognostic Value of Serum Angiopoietin-Like Protein 2 in Patients with Non-Small Cell Lung Cancer.
Chen Y; Jiang H; Zhu L; Wang P; Liu S; Xiao X; Yu H; Dong W
Clin Lab; 2017 Jan; 63(1):59-65. PubMed ID: 28164488
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
[TBL] [Abstract][Full Text] [Related]
13. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients].
Duan X; Cui Y; Gong M; Tian F; Shi G; Wu B; Liu M; Guo J; Kong Y
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):358-64. PubMed ID: 26104892
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer.
Baek AR; Seo HJ; Lee JH; Park SW; Jang AS; Paik SH; Koh ES; Shin HK; Kim DJ
Cancer Biomark; 2018; 22(1):55-62. PubMed ID: 29630519
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
[TBL] [Abstract][Full Text] [Related]
16. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic value of serum human kallikrein-related peptidases 11 in non-small cell lung cancer.
Xu CH; Zhang Y; Yu LK
Tumour Biol; 2014 Jun; 35(6):5199-203. PubMed ID: 24510347
[TBL] [Abstract][Full Text] [Related]
18. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer.
Hsu WH; Huang CS; Hsu HS; Huang WJ; Lee HC; Huang BS; Huang MH
Ann Thorac Surg; 2007 Feb; 83(2):419-24. PubMed ID: 17257963
[TBL] [Abstract][Full Text] [Related]
20. Serum level of DKK-1 and its prognostic potential in non-small cell lung cancer.
Dong LL; Qu LY; Chu LY; Zhang XH; Liu YH
Diagn Pathol; 2014 Mar; 9():52. PubMed ID: 24612589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]